Drug intelligence / Profile preview

tak-329

Development stage: Phase 1
Lead developer: Takeda
Modality: Small Molecules
Administration: Oral

Overview

TAK-329 is a small molecule drug developed by Takeda Pharmaceutical. It functions as a glucokinase activator, targeting the enzyme glucokinase to enhance its activity. Glucokinase plays a key role in glucose metabolism, and activation of this enzyme is being explored as a therapeutic strategy for metabolic diseases such as diabetes mellitus. TAK-329 was investigated primarily for type 1 diabetes mellitus, with clinical studies focused on evaluating its safety, tolerability, pharmacokinetics, and pharmacodynamics compared to rapid-acting insulin analogs[1][3][4].

Targets

GCK (Glucokinase)

Beyond the preview

Go deeper on tak-329.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tak-329.

Explore the full profile